Grant: Operating Grant: COVID-19 - Therapeutics
University of Alberta
$675,000.00
Development and Evaluation of SARS-CoV-2 RNA Polymerase Inhibitors
EF 2019-20
Résumé
Coronaviruses (CoV) can cause severe human respiratory diseases, which is documented by three major outbreaks over the past 17 years: SARS-CoV in 2003, MERS-CoV in 2012, and currently SARS-CoV-2. In response to the current COVID-19 outbreak caused by SARS-CoV-2, we propose to develop novel tools to discover, develop and evaluate inhibitors of the viral polymerase. The polymerase is an enzyme that is essentially required for the propagation of SARS-CoV-2, which makes it an attractive target for therapeutic intervention strategies.
Programme
Operating Grant: COVID-19 - Therapeutics
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
422709
Name
Götte Matthias
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Canadian 2019 Novel Coronavirus (2019-nCoV) Rapid Research
Projecttitle
Development and Evaluation of SARS-CoV-2 RNA Polymerase Inhibitors
Programtype2
Operating Grants
Orgnameinp2
University of Alberta
Cihramount2
$675,000
Cihrequipment2
$0
Programname2
Operating Grant: COVID-19 - Therapeutics
Keyworddelim
Biomedical Research: Therapeutics
Abstract
Coronaviruses (CoV) can cause severe human respiratory diseases, which is documented by three major outbreaks over the past 17 years: SARS-CoV in 2003, MERS-CoV in 2012, and currently SARS-CoV-2. In response to the current COVID-19 outbreak caused by SARS-CoV-2, we propose to develop novel tools to discover, develop and evaluate inhibitors of the viral polymerase. The polymerase is an enzyme that is essentially required for the propagation of SARS-CoV-2, which makes it an attractive target for therapeutic intervention strategies.
Competitiondate
202002
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Götte, Matthias
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $675,000~ $0~
